OraSure Technologies (OSUR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

OraSure Technologies

NasdaqGS•Healthcare•Medical Instruments & Supplies

$3.48-0.10(-0.03%)Market closed

Market Cap

$245.65M

P/S

2.2x

P/B

0.8x

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.

How this company scores

AverageMetricSide Score: 44/100

Strongest: Profitability (17/25); weakest: Cash & Earnings Quality (5/25).

Profitability17/25

Growth7/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality5/25

Strengths

Long cash runwayInterest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 28.0x5y range 8.6x – 28.0x

Currently above its 7-quarter median.

P/S · 2.2x5y range 0.7x – 3.5x

Currently above its 20-quarter median.

P/B · 0.8x5y range 0.5x – 2.1x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $245.65M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $112.41M
Q. Revenue: $30.64M
TTM EBITDA: $-44.45M
TTM Op. Income: $-54.02M
Q. Op. Income: $5.44M
TTM Net Income: $-49.13M
Q. Net Income: $6.25M
EPS: $0.09
Shares Out.: $69.00M

$112.41M in TTM revenue declined 18.9% YoY, reaching $30.64M last quarter. TTM EBITDA of $-44.45M and TTM operating income of $-54.02M show growth is flowing through to the bottom line. However, net income is negative at $49.13M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 7 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 43.5%
EBITDA Margin: 25.5%
Op. Margin: 17.8%
Net Margin: 20.4%

Op. margin of 17.8% is up 75.5% YoY — cost efficiency is improving. Net margin at 20.4% and gross margin of 43.5% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 131% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 2.2x
P/B Ratio: 0.8x

P/S of 2.2x and P/B of 0.8x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $360.55M
Cash: $160.58M
Long-Term Debt: N/A
Book Value: $317.78M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-9.92M
TTM Free Cash Flow: $-48.06M
FCF Margin: -42.8%
FCF / Net Income: 1.0

TTM FCF of $-48.06M on $-9.92M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 139% — a weakening trend.